TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10524634

Group type: EXPERIMENTAL
Intervention: UDCA 900 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: UDCA 1200 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: UDCA 300 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: UDCA 600 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: UDCA 0 mg/day (placebo)
Number of subjects: 24
Study: 8645641

Group type: EXPERIMENTAL
Intervention: Suction fetal scalp electrode
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spiral electrode
Number of subjects: 100
Study: 1617251

Group type: EXPERIMENTAL
Intervention: 2-deoxyadenosine (2-DXA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unexposed samples)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unwashed sperm without 2-DXA)
Number of subjects: 0
Study: 6387689

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31881910

Group type: EXPERIMENTAL
Intervention: High-protein total diet replacement (35% carbohydrate, 40% protein, 25% fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (55% carbohydrate, 15% protein, 30% fat)
Number of subjects: 0
Study: 30390684

Group type: EXPERIMENTAL
Intervention: GSK561679
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 27848209

Group type: EXPERIMENTAL
Intervention: FitEx
Number of subjects: 12

Group type: COMPARATOR
Intervention: ALED
Number of subjects: 12
Study: 25361836

Group type: EXPERIMENTAL
Intervention: Progression (by independent review)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression (by investigator assessment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without progression
Number of subjects: 0
Study: 22564362

Group type: EXPERIMENTAL
Intervention: Social isolation prevention program (4 sessions, group-based)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study: 20932411

Group type: EXPERIMENTAL
Intervention: Cetrorelix pamoate 60 mg followed by 30 mg after 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetrorelix pamoate (various dosages: 30 + 30 mg, 30 + 30 + 30 mg, 60 + 30 mg, 60 + 60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17902131

Group type: EXPERIMENTAL
Intervention: Modified double perfusion (MDP) technique
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single aortic perfusion (SAP) technique
Number of subjects: 35
Study: 15618380

Group type: EXPERIMENTAL
Intervention: Radiography plus immediate MR imaging
Number of subjects: 189

Group type: COMPARATOR
Intervention: Radiography only
Number of subjects: 189
Study: 12386644

Group type: EXPERIMENTAL
Intervention: High-profile infusion (total dose of rilmenidine, 3.3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-profile infusion (total dose of rilmenidine, 1.45 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10429007

Group type: EXPERIMENTAL
Intervention: Cotton swab technique
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cotton swab technique (immediate plating)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cotton swab technique (transported samples)
Number of subjects: 50
Study: 7748969

Group type: EXPERIMENTAL
Intervention: 4 mg/kg loading dose (LD) of gentamicin
Number of subjects: 26

Group type: COMPARATOR
Intervention: 2.5 mg/kg every 12, 18 or 24 h (control group)
Number of subjects: 26
Study: 1987948

Group type: EXPERIMENTAL
Intervention: 1.8% sezolamide hydrochloride (MK-417)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6849145

Group type: EXPERIMENTAL
Intervention: Low spinal anaesthesia using hyperbaric cinchocaine (Nupercaine; Ciba) 0.25% combined with local anaesthetic abdominal wall infiltration
Number of subjects: 0
Study: 29792556

Group type: EXPERIMENTAL
Intervention: Wii training plus usual care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 40
Study: 30525258

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole breast irradiation (WBI)
Number of subjects: 0
Study: 30033879

Group type: EXPERIMENTAL
Intervention: Curcumin oral supplementation (600 mg/day, Brai‐noil) for 6 months (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 3 months followed by Curcumin (Group A)
Number of subjects: 0
Study: 27102321

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Community-based exercise program
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study: 25101637

Group type: EXPERIMENTAL
Intervention: Real acupuncture (REAL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Phantom acupuncture (PHNT)
Number of subjects: 20
Study: 22367417

Group type: EXPERIMENTAL
Intervention: Citalopram plus paliperidone (20 mg/day + 3 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Citalopram (20 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Citalopram plus paliperidone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 60
Study: 19653176

Group type: EXPERIMENTAL
Intervention: Transradial approach (group I; n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transfemoral approach (group II; n = 50)
Number of subjects: 100
Study: 17451796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 55
Study: 15924781

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/d
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pravastatin (both dosages)
Number of subjects: 108
Study: 11952433

Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 1.0 ml/s
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 0.2 ml/s
Number of subjects: 30
Study: 9593390

Group type: EXPERIMENTAL
Intervention: Marcus Gunn test
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alternating light test
Number of subjects: 14
Study: 7542473

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus interferon (IFN) at a dosage of 5.0 MU three times weekly during the first year
Number of subjects: 103

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus interferon (IFN)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 2093956

Group type: EXPERIMENTAL
Intervention: Weekly interruption digoxin dosage (2 days interruption per week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous digoxin dosage (uninterrupted)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Comparison of both dosages
Number of subjects: 14
Study: 444354

Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg) in capsule form
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg) in tablet form
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg)
Number of subjects: 12
Study: 30602032

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 3 months
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 2 months
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 28936792

Group type: EXPERIMENTAL
Intervention: Alpha/Theta neurofeedback training (NFG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waiting list group (WLG)
Number of subjects: 44
Study: 26430694

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg/day, four doses of 625 mg calcium carbonate for 1 month)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 75
Study: 24219374

Group type: EXPERIMENTAL
Intervention: Iron-fortified flavored skim milk (500 mL/day)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Iron and vitamin D-fortified flavored skim milk (500 mL/day)
Number of subjects: 109
Study: 22517917

Group type: EXPERIMENTAL
Intervention: SPARX (computerised cognitive behavioural therapy)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Treatment as usual (face to face counselling)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: SPARX
Number of subjects: 187

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 187
Study: 19786600

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: C. glabrata
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall breakthrough infections
Number of subjects: 0
Study: 17515289

Group type: EXPERIMENTAL
Intervention: Emiphage (test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Commercially available original preparation (reference)
Number of subjects: 24
Study: 15510930

Group type: EXPERIMENTAL
Intervention: Premelle (Premarin 0.625 mg plus medroxyprogesterone acetate 2.5 mg/tablet orally)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 11394593

Group type: EXPERIMENTAL
Intervention: Autogenous bone‐patellar tendon‐bone graft (group 1)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Semitendinosus and gracilis tendon graft reconstruction combined with an extraarticular procedure (group 2)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Semitendinosus and gracilis tendon graft reconstruction alone (group 3)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Overall knee rating
Number of subjects: 102
Study: 10399111

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg daily
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 8301442

Group type: EXPERIMENTAL
Intervention: 2.5 ml/kg surfactant
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 5.0 ml/kg surfactant
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 7.5 ml/kg surfactant
Number of subjects: 281

Group type: COMPARATOR
Intervention: Air placebo (5.0 ml/kg)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 5.0 and 7.5 ml/kg surfactant
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Standard two 5.0 ml/kg rescue doses
Number of subjects: 281
Study: 3132868

Group type: EXPERIMENTAL
Intervention: NTG solution (2 mg/3 ml) intranasally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (3 ml) intranasally
Number of subjects: 30
Study: 31828504

Group type: EXPERIMENTAL
Intervention: Low recruiters (recruitment rate below median)
Number of subjects: 15991

Group type: COMPARATOR
Intervention: High recruiters (recruitment rate above median)
Number of subjects: 15991

Group type: COMPARATOR
Intervention: Patients who withdrew consent (incomplete follow-up)
Number of subjects: 15991
Study: 30089410

Group type: EXPERIMENTAL
Intervention: Carnosine supplementation (500 mg daily for two months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (500 mg daily for two months)
Number of subjects: 36
Study: 28471913

Group type: EXPERIMENTAL
Intervention: In-line digestive cartridge (Relizorb)
Number of subjects: 0
Study: 25439118

Group type: EXPERIMENTAL
Intervention: Epidural self‐controlled analgesia (EA group, n = 26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural self‐controlled analgesia (EA group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous self‐controlled analgesia (IA group, n = 24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous self‐controlled analgesia (IA group)
Number of subjects: 50
Study: 22843044

Group type: EXPERIMENTAL
Intervention: Kettlebell training (3 times a week for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 21993032

Group type: EXPERIMENTAL
Intervention: Static passive stretching (P)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Static active stretching in active tension (AT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Static active stretching in passive tension (PT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No stretching (NS)
Number of subjects: 49
Study: 19168918

Group type: EXPERIMENTAL
Intervention: Jumping (n = 61)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Nutrition (n = 9)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Jumping plus Nutrition (n = 14)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (n = 28)
Number of subjects: 112
Study: 16600463

Group type: EXPERIMENTAL
Intervention: Mandibular two‐implant overdentures
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 140
Study: 12645832

Group type: EXPERIMENTAL
Intervention: 200 mg 1.8-cineol t.i.d.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10752099

Group type: EXPERIMENTAL
Intervention: Adult spondylolisthesis patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: Chronic low back pain patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patients with nonorganic pain drawing
Number of subjects: 150
Study: 9350554

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalers + prophy cups
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalers + prophy cups + dental floss
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gracey curettes + prophy cups
Number of subjects: 12
Study: 8457308

Group type: EXPERIMENTAL
Intervention: Treatment for cupulolithiasis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment for canalithiasis
Number of subjects: 60
Study: 3089490

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 25
Study: 29330911

Group type: EXPERIMENTAL
Intervention: Increased arterial stiffness measured by pulse wave velocity (PWV)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Increased osteoprotegerin (OPG) plasma levels
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) as a predictor of major adverse cardiovascular events (MACE)
Number of subjects: 262
Study: 26820653

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 25547247

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 100
Study: 22459636

Group type: EXPERIMENTAL
Intervention: Traditional health promotion program for employees
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Activated consumer program
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control program
Number of subjects: 320
Study: 20073074

Group type: EXPERIMENTAL
Intervention: Plasma knife dissection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bipolar electrocautery with cold knife
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plasma knife parotidectomy
Number of subjects: 40
Study: 18929612

Group type: EXPERIMENTAL
Intervention: High-SPQ group during letter VFT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-SPQ group during letter VFT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-SPQ group during category VFT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-SPQ group during category VFT
Number of subjects: 32
Study: 17135854

Group type: EXPERIMENTAL
Intervention: Intervention cohort (n = 67) with systematic reminders to PCPs and cardiologists regarding lipid goals and therapeutic options.
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control cohort (n = 178) without systematic reminders.
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Intervention cohort (n = 67) with lipid medication change during CR.
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control cohort (n = 178) with lipid medication change during CR.
Number of subjects: 245
Study: 12627040

Group type: EXPERIMENTAL
Intervention: Soy protein with a medium dose of isoflavones (42 mg/day)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Soy protein with a higher dose of isoflavones (58 mg/day)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Isoflavone extracted soy protein (control)
Number of subjects: 241
Study: 10834771

Group type: EXPERIMENTAL
Intervention: Anxious children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 0
Study: 9086005

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (mean 21% of calories from fat, 61% of calories from carbohydrates)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Control group (mean 32% of calories from fat, 50% of calories from carbohydrates)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet
Number of subjects: 817
Study: 1586360

Group type: EXPERIMENTAL
Intervention: Cue exposure and response prevention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Self-control techniques
Number of subjects: 12
Study: 2862933

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 48
Study: 31023345

Group type: EXPERIMENTAL
Intervention: Parent mentor with an experimental curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent mentor with a standard curriculum (active control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 29697276

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (UGFNA)
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Palpation-guided fine-needle aspiration (PGFNA)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (UGFNA) for thyroid lesions
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Palpation-guided fine-needle aspiration (PGFNA) for thyroid lesions
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (UGFNA) for head and neck lesions
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Palpation-guided fine-needle aspiration (PGFNA) for head and neck lesions
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (UGFNA) for salivary gland lesions
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Palpation-guided fine-needle aspiration (PGFNA) for salivary gland lesions
Number of subjects: 1029
Study: 27212766

Group type: EXPERIMENTAL
Intervention: Psoas compartment block (PCB) combined with sciatic nerve block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 90
Study: 25372004

Group type: EXPERIMENTAL
Intervention: Anodal stimulation of the primary motor cortex (tDCS, 1 mA for 20 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo transcranial stimulation
Number of subjects: 20
Study: 22858697

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (10 mmol/L)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no ferrous sulfate)
Number of subjects: 10
Study: 19910548

Group type: EXPERIMENTAL
Intervention: 1 drink/wk
Number of subjects: 21860

Group type: COMPARATOR
Intervention: <1 drink/wk
Number of subjects: 21860
Study: 18182830

Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tryptophan-balanced amino acid mixture (BAL)
Number of subjects: 22
Study: 15064585

Group type: EXPERIMENTAL
Intervention: r-hEPO administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no r-hEPO administration)
Number of subjects: 0
Study: 11394604

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (5 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 9721822

Group type: EXPERIMENTAL
Intervention: Paroxetine (N = 20)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (N = 10)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (N = 8)
Number of subjects: 38
Study: 7993153

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (200 micrograms once daily)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Terfenadine tablets (60 mg twice daily)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate
Number of subjects: 232

Group type: COMPARATOR
Intervention: Terfenadine tablets
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 232
Study: 2786959

Group type: COMPARATOR
Intervention: Toothbrushing only
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Three types of dental floss
Number of subjects: 119
Study: 31973633

Group type: EXPERIMENTAL
Intervention: Home telemonitoring system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 30755054

Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: RV‐to‐pulmonary artery shunt
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: RV ejection fraction <40% at 14 months
Number of subjects: 241
Study: 27135960

Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (20 mg/kg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (3 g/100 mL saline)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 123
Study: 25453395

Group type: EXPERIMENTAL
Intervention: Personalized diet alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Personalized diet with VSL#3 (2 capsules per day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: VSL#3 in subgroup with low-grade inflammation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 62